AbbVie Faces Competition from New Drug Threat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion with a year-over-year increase of 12.4%, indicating robust overall business health despite looming competitive pressures.
- Skyrizi's Market Position: Skyrizi holds over 45% of the U.S. biologic psoriasis market, generating $17.6 billion in revenue last year with a 49.9% year-over-year growth rate, solidifying its leadership in a highly competitive landscape.
- Emerging Competitive Threat: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, potentially surpassing Skyrizi's 51%, leading to positive market reactions for Oruka and downward pressure on AbbVie's stock.
- Diversified Growth Drivers: Despite competitive threats, AbbVie has other growth drivers such as Qulipta and Botox, along with a strong pipeline expected to yield new products, thereby reducing reliance on its immunology segment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 208.500
Low
223.00
Averages
252.00
High
289.00
Current: 208.500
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie: A Healthcare Stock Worth Considering for Long-Term Investment
- Strong Product Line: AbbVie boasts 12 blockbuster drugs generating over $1 billion in revenue, with 2025 performance highlighting its robust competitive position in the healthcare sector, further solidifying its status as an industry leader.
- Substantial R&D Investment: Since 2013, AbbVie has invested over $85 billion in R&D, focusing on approximately 90 new therapies, with 60 in mid-to-late stage development, showcasing its potential for future growth and innovation.
- Stable Dividend Returns: AbbVie offers a dividend yield of 3.4%, with payouts increasing over 330% since 2013, reaching $6.92 per share in 2023, making it attractive for long-term investors seeking reliable income.
- Reasonable Valuation Levels: Although AbbVie’s P/E ratio stands at 14, slightly above its five-year average of 13, its first-quarter revenue growth of 12.4%, along with strong performances from Skyrizi and Rinvoq, indicates significant investment value.
See More
Oncotelic Launches Innovative Brain Drug Delivery System
- Breakthrough Delivery Technology: Oncotelic Therapeutics' N2B system enables rapid drug delivery to the brain, marking a consensus in the biopharma industry that delivery innovation will drive significant breakthroughs in central nervous system (CNS) medicine.
- Strategic Partnership Agreement: Oncotelic has finalized a strategic agreement with Lunai Bioworks, transferring global rights to the N2B system for applications in biodefense and Alzheimer's disease, highlighting the company's strategic focus on drug delivery infrastructure.
- Global Challenge of Alzheimer's: Approximately 57 million people worldwide currently live with dementia, a figure projected to rise sharply with aging populations, and Oncotelic's technology aims to provide more effective treatment solutions in this area.
- Dual Market Potential: The N2B system from Oncotelic addresses not only chronic diseases but also national security and biodefense needs, reflecting the broad applicability of its technology in both commercial medicine and government-funded projects.
See More
SureNano Science Develops Next-Gen GLP-1 Therapy GEP-44
- Significant Market Potential: The global GLP-1 market is projected to reach $190 billion by 2035, and SureNano Science aims to capitalize on this rapidly growing market by developing GEP-44, a next-generation triple agonist that enhances its competitiveness in obesity and metabolic disease treatment.
- Innovative Therapy Development: GEP-44 is designed as a patented metabolic therapy to address the limitations of first-generation GLP-1 drugs, targeting GLP-1 alongside peptide YY receptors Y1 and Y2, which may significantly improve patient tolerability and treatment outcomes, thereby facilitating successful FDA approval.
- Positive Preclinical Data: SureNano's preclinical studies indicate that GEP-44 achieves approximately 15% weight loss compared to 9% with traditional drugs, while also avoiding common side effects like nausea and gastrointestinal discomfort, potentially establishing a competitive edge in the future market.
- Delivery Technology Innovation: SureNano is exploring non-injection delivery technologies, including oral and sublingual methods, to enhance patient accessibility and long-term adherence, a strategy that not only improves patient experience but may also create new commercial opportunities in a competitive landscape.
See More
Oncotelic Launches Innovative Brain Drug Delivery System
- Breakthrough Delivery Technology: Oncotelic Therapeutics' N2B delivery system enables rapid transport of therapeutics to the brain, marking a consensus in the biopharma industry that delivery innovation will drive the next wave of breakthroughs in CNS medicine.
- Strategic Partnership Agreement: Oncotelic has finalized a strategic monetization agreement with Lunai Bioworks, granting global rights to the N2B delivery system for biodefense and Alzheimer's applications, highlighting the company's strategic focus on core asset control.
- Global Alzheimer's Challenge: Approximately 57 million people worldwide currently live with dementia, a figure projected to rise sharply with aging populations, and Oncotelic's technology aims to address the delivery bottleneck to improve treatment outcomes.
- Dual Market Potential: Oncotelic's delivery technology is applicable not only to chronic diseases but also to national security and biodefense needs, reflecting its broad applicability in both commercial medicine and government-funded initiatives.
See More
AbbVie's Strong Earnings Amid Competitive Threats
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion and reflecting a 12.4% year-over-year growth, indicating robust market performance and a solid financial foundation.
- Immunology Segment Dominance: AbbVie's key growth drivers, Skyrizi and Rinvoq, generated $17.6 billion and $8.3 billion in revenue last year, respectively, with Skyrizi's year-over-year growth rate reaching 49.9%, solidifying its market leadership.
- Rising Competitive Risks: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, posing a potential threat to Skyrizi, which typically achieves only 51%, leading to positive market reactions to Oruka's results.
- Diversified Growth Strategy: Despite competitive pressures, AbbVie has other growth drivers like Qulipta and Botox, and is developing new products to reduce reliance on its immunology business, maintaining long-term attractiveness and a strong dividend policy.
See More
AbbVie Faces Competition from New Drug Threat
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion with a year-over-year increase of 12.4%, indicating robust overall business health despite looming competitive pressures.
- Skyrizi's Market Position: Skyrizi holds over 45% of the U.S. biologic psoriasis market, generating $17.6 billion in revenue last year with a 49.9% year-over-year growth rate, solidifying its leadership in a highly competitive landscape.
- Emerging Competitive Threat: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, potentially surpassing Skyrizi's 51%, leading to positive market reactions for Oruka and downward pressure on AbbVie's stock.
- Diversified Growth Drivers: Despite competitive threats, AbbVie has other growth drivers such as Qulipta and Botox, along with a strong pipeline expected to yield new products, thereby reducing reliance on its immunology segment.
See More
AbbVie: A Healthcare Stock Worth Considering for Long-Term Investment
- Strong Product Line: AbbVie boasts 12 blockbuster drugs generating over $1 billion in revenue, with 2025 performance highlighting its robust competitive position in the healthcare sector, further solidifying its status as an industry leader.
- Substantial R&D Investment: Since 2013, AbbVie has invested over $85 billion in R&D, focusing on approximately 90 new therapies, with 60 in mid-to-late stage development, showcasing its potential for future growth and innovation.
- Stable Dividend Returns: AbbVie offers a dividend yield of 3.4%, with payouts increasing over 330% since 2013, reaching $6.92 per share in 2023, making it attractive for long-term investors seeking reliable income.
- Reasonable Valuation Levels: Although AbbVie’s P/E ratio stands at 14, slightly above its five-year average of 13, its first-quarter revenue growth of 12.4%, along with strong performances from Skyrizi and Rinvoq, indicates significant investment value.
See More
Oncotelic Launches Innovative Brain Drug Delivery System
- Breakthrough Delivery Technology: Oncotelic Therapeutics' N2B system enables rapid drug delivery to the brain, marking a consensus in the biopharma industry that delivery innovation will drive significant breakthroughs in central nervous system (CNS) medicine.
- Strategic Partnership Agreement: Oncotelic has finalized a strategic agreement with Lunai Bioworks, transferring global rights to the N2B system for applications in biodefense and Alzheimer's disease, highlighting the company's strategic focus on drug delivery infrastructure.
- Global Challenge of Alzheimer's: Approximately 57 million people worldwide currently live with dementia, a figure projected to rise sharply with aging populations, and Oncotelic's technology aims to provide more effective treatment solutions in this area.
- Dual Market Potential: The N2B system from Oncotelic addresses not only chronic diseases but also national security and biodefense needs, reflecting the broad applicability of its technology in both commercial medicine and government-funded projects.
See More
SureNano Science Develops Next-Gen GLP-1 Therapy GEP-44
- Significant Market Potential: The global GLP-1 market is projected to reach $190 billion by 2035, and SureNano Science aims to capitalize on this rapidly growing market by developing GEP-44, a next-generation triple agonist that enhances its competitiveness in obesity and metabolic disease treatment.
- Innovative Therapy Development: GEP-44 is designed as a patented metabolic therapy to address the limitations of first-generation GLP-1 drugs, targeting GLP-1 alongside peptide YY receptors Y1 and Y2, which may significantly improve patient tolerability and treatment outcomes, thereby facilitating successful FDA approval.
- Positive Preclinical Data: SureNano's preclinical studies indicate that GEP-44 achieves approximately 15% weight loss compared to 9% with traditional drugs, while also avoiding common side effects like nausea and gastrointestinal discomfort, potentially establishing a competitive edge in the future market.
- Delivery Technology Innovation: SureNano is exploring non-injection delivery technologies, including oral and sublingual methods, to enhance patient accessibility and long-term adherence, a strategy that not only improves patient experience but may also create new commercial opportunities in a competitive landscape.
See More
Oncotelic Launches Innovative Brain Drug Delivery System
- Breakthrough Delivery Technology: Oncotelic Therapeutics' N2B delivery system enables rapid transport of therapeutics to the brain, marking a consensus in the biopharma industry that delivery innovation will drive the next wave of breakthroughs in CNS medicine.
- Strategic Partnership Agreement: Oncotelic has finalized a strategic monetization agreement with Lunai Bioworks, granting global rights to the N2B delivery system for biodefense and Alzheimer's applications, highlighting the company's strategic focus on core asset control.
- Global Alzheimer's Challenge: Approximately 57 million people worldwide currently live with dementia, a figure projected to rise sharply with aging populations, and Oncotelic's technology aims to address the delivery bottleneck to improve treatment outcomes.
- Dual Market Potential: Oncotelic's delivery technology is applicable not only to chronic diseases but also to national security and biodefense needs, reflecting its broad applicability in both commercial medicine and government-funded initiatives.
See More
AbbVie's Strong Earnings Amid Competitive Threats
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion and reflecting a 12.4% year-over-year growth, indicating robust market performance and a solid financial foundation.
- Immunology Segment Dominance: AbbVie's key growth drivers, Skyrizi and Rinvoq, generated $17.6 billion and $8.3 billion in revenue last year, respectively, with Skyrizi's year-over-year growth rate reaching 49.9%, solidifying its market leadership.
- Rising Competitive Risks: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, posing a potential threat to Skyrizi, which typically achieves only 51%, leading to positive market reactions to Oruka's results.
- Diversified Growth Strategy: Despite competitive pressures, AbbVie has other growth drivers like Qulipta and Botox, and is developing new products to reduce reliance on its immunology business, maintaining long-term attractiveness and a strong dividend policy.
See More
AbbVie Faces Competition from New Drug Threat
- Strong Financial Performance: AbbVie reported $15 billion in revenue for Q1, exceeding its guidance of $14.7 billion with a year-over-year increase of 12.4%, indicating robust overall business health despite looming competitive pressures.
- Skyrizi's Market Position: Skyrizi holds over 45% of the U.S. biologic psoriasis market, generating $17.6 billion in revenue last year with a 49.9% year-over-year growth rate, solidifying its leadership in a highly competitive landscape.
- Emerging Competitive Threat: Oruka Therapeutics' ORKA-001 demonstrated a 63.5% PASI 100 achievement rate in clinical trials, potentially surpassing Skyrizi's 51%, leading to positive market reactions for Oruka and downward pressure on AbbVie's stock.
- Diversified Growth Drivers: Despite competitive threats, AbbVie has other growth drivers such as Qulipta and Botox, along with a strong pipeline expected to yield new products, thereby reducing reliance on its immunology segment.
See More
